The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Open accessAbstract
OBJECTIVE: To appraise the evidence for comparative efficacy and tolerability of drug treatments in patients with generalised anxiety disorder. DESIGN: Systematic review of randomised controlled trials. Primary Bayesian probabilistic mixed treatment meta-analyses allowed pharmacological treatments to be ranked for effectiveness for each outcome measure, given as percentage probability of being the most effective treatment. Secondary frequentist mixed treatment meta-analyses conducted with random effects model; effect size reported as odds ratio and 95% confidence interval. DATA SOURCES: Medline, Embase, BIOSIS, PsycINFO, Health Economic Evaluations Database, National Health Service Economic Evaluation Database, and Database of Abstracts of Reviews of Effects via DataStar, and Cochrane Database of Systematic Reviews via Cochrane Library (January 1980 to February 2009). Eligibility criteria Double blind placebo controlled randomised controlled trials; published systematic reviews and meta-analyses of randomised controlled trials. Randomised controlled trials including adult participants (aged ≥ 18) receiving any pharmacological treatment for generalised anxiety disorder. Data abstraction methods Titles or abstracts reviewed initially, followed by review of full text publications for citations remaining after first pass. A three person team conducted screening; an independent reviewer checked a random selection (10%) of articles screened. Data extracted for meta-analysis were also independently reviewed. MAIN OUTCOME MEASURES: Proportion of participants experiencing ≥ 50% reduction from baseline score on Hamilton anxiety scale (HAM-A) (response), proportion with final HAM-A score ≤ 7 (remission), proportion withdrawing from trial because of adverse events (tolerability). RESULTS: The review identified 3249 citations, and 46 randomised controlled trials met inclusion criteria; 27 trials contained sufficient or appropriate data for inclusion in the analysis. Analyses compared nine drugs (duloxetine, escitalopram, fluoxetine, lorazepam, paroxetine, pregabalin, sertraline, tiagabine, and venlafaxine). In the primary probabilistic mixed treatment meta-analyses, fluoxetine was ranked first for response and remission (probability of 62.9% and 60.6%, respectively) and sertraline was ranked first for tolerability (49.3%). In a subanalysis ranking treatments for generalised anxiety disorder currently licensed in the United Kingdom, duloxetine was ranked first for response (third across all treatments; 2.7%), escitalopram was ranked first for remission (second across all treatments; 26.7%), and pregabalin was ranked first for tolerability (second across all treatments; 7.7%). CONCLUSIONS: Though the frequentist analysis was inconclusive because of a high level of uncertainty in effect sizes (based on the relatively small number of comparative trials), the probabilistic analysis, which did not rely on significant outcomes, showed that fluoxetine (in terms of response and remission) and sertraline (in terms of tolerability) seem to have some advantages over other treatments. Among five UK licensed treatments, duloxetine, escitalopram, and pregabalin might offer some advantages over venlafaxine and paroxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility
Lunn, D. J., Thomas, A., Best, N., & Spiegelhalter, D. (2000) · Statistics and Computing · doi:10.1023/a:1008929526011 · Cited by 5,368
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
(1920) · British Journal of Ophthalmology · doi:10.1136/bjo.4.1.25 · Cited by 1,606
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · cited 1×
“For the analyses in WinBUGS, every sample consisted of 20 000 iterations with an initial burn-in period of 1000 iterations. The model framework, stratified by study, included univariate random effects to allow for apparent heterogeneity between studies in the treatment comparison effects. The probability of the outcom…”
MethodEvaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Bayesian methods in meta-analysis and evidence synthesis
Sutton, A. J., & Abrams, K. R. (2001) · Statistical Methods in Medical Research · doi:10.1177/096228020101000404 · Cited by 710
(2002) · PubMed · Cited by 518
Human and economic burden of generalized anxiety disorder
Hoffman, D. L., Dukes, E. M., & Wittchen, H.-U. (2008) · Depression and Anxiety · doi:10.1002/da.20257 · Cited by 438
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Optogenetic investigation of neural circuits underlying brain disease in animal models
Tye, K. M., & Deisseroth, K. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3171 · Cited by 745
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…studies with duloxetine [I (M)] (Pollack et al., 2008), escitalopram [I (M) (Baldwin et al., 2009), and with alprazolam, pregabalin and venlafaxine [I (M) (Baldwin et al., 2011a) all suggest that response is likely only if there is an onset of effect within four weeks of treatment.”
BackgroundMethodInfluentialSelf-citationSlee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Benzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis
Mills, E. J., Ioannidis, J. P. A., Thorlund, K., Schünemann, H. J., Puhan, M. A., & Guyatt, G. H. (2012) · JAMA · doi:10.1001/2012.jama.11228 · Cited by 360
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Costello, H., Gould, R. L., Abrol, E., & Howard, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027925 · Cited by 248
(2015) · PubMed · Cited by 229
DeMartini, J., Patel, G., & Fancher, T. L. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201904020 · Cited by 226
Dell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
“BZDs are not recommended in the treatment of depressive disorders as they have no antidepressant effects [13,89].”
BackgroundPharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Reis, D. J., Ilardi, S. S., & Punt, S. E. W. (2018) · PLOS ONE · doi:10.1371/journal.pone.0199041 · Cited by 123
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Self-citationNo end in sight: benzodiazepine use in older adults in the United States.
Maust, D. T., Kales, H. C., Wiechers, I. R., Blow, F. C., & Olfson, M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14379 · Cited by 82
Gersh, E., Hallford, D. J., Rice, S. M., Kazantzis, N., Gersh, H., Gersh, B., & McCarty, C. A. (2017) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2017.10.001 · Cited by 82
El Dib, R., Periyasamy, A. G., de Barros, J. L., França, C. G., Senefonte, F. L., Vesentini, G., Alves, M. G. O., Rodrigues, J. V. D. S., Gomaa, H., Gomes Júnior, J. R., et al. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.07.027 · Cited by 75
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Agomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Howard, P., Twycross, R., Shuster, J., Mihalyo, M., & Wilcock, A. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2014.03.001 · Cited by 64
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Anxious to see you: Neuroendocrine mechanisms of social vigilance and anxiety during adolescence
Wright, E. C., Hostinar, C. E., & Trainor, B. C. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14628 · Cited by 55
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Han, K., Wang, J.-Y., Wang, P.-Y., & Peng, Y.-C.-H. (2024) · Psychiatry research · doi:10.1016/j.psychres.2024.116049 · Cited by 54
Comprehensive review of generalized anxiety disorder in primary care in Europe.
Parmentier, H., García-Campayo, J., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.770731 · Cited by 37
Amini-Khoei, H., Nasiri Boroujeni, S., Maghsoudi, F., Rahimi-Madiseh, M., Bijad, E., Moradi, M., & Lorigooini, Z. (2022) · Behavioral and Brain Functions · doi:10.1186/s12993-022-00189-1 · Cited by 28
Willard, S. L., Uberseder, B., Clark, A., Daunais, J. B., Johnston, W. D., Neely, D., Massey, A., Williamson, J. D., Kraft, R. A., Bourland, J. D., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.011 · Cited by 25
Maneeton, N., Maneeton, B., Likhitsatian, S., Suttajit, S., Narkpongphun, A., Srisurapanont, M., & Woottiluk, P. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s79071 · Cited by 27
“Accordingly, tolerability, defined as proportion withdrawal from study because of adverse events, estimated from the rate of discontinuation due to adverse events was considered as tolerability.(19,20)”
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study
Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000139 · Cited by 13
Maneeton, N., Woottiluk, P., Suttajit, S., Likhitsathian, S., Charnsil, C., Srisurapanont, M., & Maneeton, B. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91765 · Cited by 12
Generalized anxiety disorder: Assessment and treatment
Gerlach, A. L., & Stevens, S. (2014) · The Wiley Handbook of Anxiety Disorders · doi:10.1002/9781118775349.ch48 · Cited by 3
Anxiety and Fear-Related Disorders: Generalized Anxiety Disorder
Rosellini, A. J., & Brown, T. A. (2024) · Tasman’s Psychiatry · doi:10.1007/978-3-030-51366-5_74 · Cited by 1
Metadata
- Authors
- Baldwin, D., Woods, R., Lawson, R., & Taylor, D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2011-03-11
- Volume
- 342
- Issue
- mar11 1
- Pages
- d1199-d1199
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2066770086
- Cited by
- 285
- References
- 64
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.